Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion "X-VERT"


Phase 3 Results



  • Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, Hohnloser SH; X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014 Dec 14;35(47):3346-55. doi: 10.1093/eurheartj/ehu367. Epub 2014 Sep 2. Pubmed ID:25182247
  • Retraction of: 'Cardiac paraganglioma' [Eur Heart J, doi: 10.1093/eurheartj/ehu241. Published online 18 June 2014]. Zhong Hai and Shao Guangrui. Eur Heart J. 2014 Jun 18. pii: ehu241. [Epub ahead of print] Pubmed ID:24944325

Related Links

Sources for Trial Information